Latest Ophthalix Inc (OPLI) Headlines Can-Fit
Post# of 5
Can-Fite Completes $5 Million Private Placement
PR Newswire - Mon Mar 10, 11:44AM CDT
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has closed a private placement with mostly US healthcare focused institutional investors resulting in gross proceeds of $5 million.
Can-Fite Announces the Addition of A Key Opinion Leader to Boost its Rheumatoid Arthritis CF101 Program
PR Newswire - Mon Mar 03, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the addition of a key opinion leader, medical and industry expert, Dr. Lee S. Simon, as consultant to assist in the regulatory and clinical development of the company's CF101 rheumatoid arthritis program.
Can-Fite to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Thu Feb 27, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 26th Annual ROTH Conference. The conference will be held on March 9-12, 2014 at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Can-Fite Granted Patent on the Manufacturing of CF101 in Japan
PR Newswire - Tue Feb 25, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Japan Patent Office (JPO) has granted a Japanese patent which bears the Patent No. 5467872 and is titled "Process for the Synthesis of IB-MECA". This patent describes a method for the chemical synthesis of the A3 adenosine receptor agonist, IB-MECA, which is the active pharmaceuticals ingredient (API) of the CF101 drug candidate. Under its patent rights, Can-Fite will have exclusive rights for the manufacturing of CF101 in Japan till 2028.
Can-Fite Provides Update on Key Milestones for 2014
PR Newswire - Tue Feb 18, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's development plan for 2014.
Can-Fite Comments on Global Rheumatoid Arthritis Market Opportunity
PR Newswire - Tue Feb 11, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today commented on the overall growth of the global rheumatoid arthritis market opportunity and the potential impact for the Company's proprietary drug CF101.
Can-Fite Submitted Phase II Study Protocol with CF102 to Treat Patients with Advanced Liver Cancer
PR Newswire - Thu Feb 06, 6:00AM CST
Can-Fite BioPharma (TASE: CFBI), (OTC: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 drug candidate has been submitted.
Can-Fite to Present at Two Upcoming Healthcare Investor Conferences
PR Newswire - Tue Jan 07, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF), (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that it is scheduled to present at two upcoming healthcare investor conferences in San Francisco, California.
OphthaliX to Retrospectively Analyze Phase III Dry Eye Syndrome Study Data Based on A3 Adenosine Receptor Biomarker
PR Newswire - Tue Dec 31, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the following:
OphthaliX to Conduct a Retrospective Analysis of the Phase III Dry Eye Syndrome Study Data Based on the A3 Adenosine Receptor Biomarker
PR Newswire - Tue Dec 31, 6:00AM CST
OphthaliX Inc. (OTCQB: OPLI), announced today that it will conduct a retrospective analysis of the Phase III Dry Eye Syndrome study data to determine if there is a correlation between the CF101 target, the A3 adenosine receptor, expression and patients' response to the drug. This analysis is based on recent positive data from a Phase IIb Rheumatoid Arthritis study of CF101 conducted by OphthaliX's parent company, Can-Fite BioPharma Ltd., where patients were enrolled based on the expression level of the A3 adenosine receptor biomarker.
OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome
PR Newswire - Mon Dec 30, 12:30AM CST
OphthaliX Inc. (OTCQB: OPLI), announced today results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist. The patients were randomized to receive two oral doses of CF101 (0.1 mg or 1.0 mg) or a placebo, for a period of 24 weeks.
Can-Fite BioPharma Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis
PR Newswire - Mon Dec 23, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist. The study entailed 2 arms, a placebo and a CF101 1 mg treated group, in which CF101 was administered orally twice-daily as a monotherapy for 12 weeks to patients with RA. Only patients with elevated baseline expression levels of the biomarker A3AR were enrolled in the study.
Can-Fite Granted U.S. Patent for Utilization of A3 Adenosine Receptor as Biomarker to Predict Patient Response to CF101 in Autoimmune Inflammatory Indications
PR Newswire - Thu Dec 19, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today, that the U.S. Patent and Trademark Office granted the Company a patent which bears the Patent No. 8,541,182 and is titled "A Biological Marker for Inflammation". The patent was granted on September 24, 2013 and will be valid until 2026, protecting Can-Fite's findings relating to the utilization of the A3 Adenosine Receptor ("A3AR") as a biomarker to predict patients' response to CF101 in autoimmune inflammatory indications.
Can-Fite CEO Issues Letter to Shareholders
PR Newswire - Wed Dec 11, 6:00AM CST
Can-Fite BioPharma (NYSE MKT: CANF), (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address anti-inflammatory and cancer diseases, today issued a Letter to Shareholders.
Can-Fite CEO to Ring Opening Bell at New York Stock Exchange
PR Newswire - Mon Dec 02, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF), (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, is pleased to announce that its CEO Dr. Pnina Fishman will ring The Opening Bell at the New York Stock Exchange (NYSE), on Thursday, December 5, 2013, to commemorate Can-Fite's recent listing on the NYSE MKT.
Can-Fite BioPharma Announces Approval of ADR Listing on NYSE MKT
PR Newswire - Fri Nov 15, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (OTCQB: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Level II American Depository Receipts ("ADRs") have been approved for listing on the NYSE MKT. Trading is expected to commence on the NYSE MKT on Tuesday, November 19, 2013 under the ticker symbol "CANF". Prior to that date, Can-Fite's ADRs will continue to trade on the U.S. Over-the-Counter Markets (OTCQB: CANFY).
Can-Fite BioPharma to Conduct U.S. Road Show on November 18 - 21, 2013
PR Newswire - Mon Nov 11, 6:00AM CST
On the heels of its European road show, Can-Fite BioPharma (TASE: CFBI), (OTCQB: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Company's CEO Dr. Pnina Fishman is scheduled to conduct a non-deal road show in the U.S. on November 18th through 21st. Group presentations and one-on-one meetings are scheduled in New York City for November 18th and in Boston for November 19th, 20th, and 21st.
U.S. Patent and Trademark Office Grants a Patent for the Reduction of Intraocular Pressure
PR Newswire - Tue Nov 05, 12:08PM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (OTCQB: CANFY), a biotechnology company developing a pipeline of small molecule drugs that address inflammatory and cancer diseases, and its subsidiary, OphthaliX Inc.(OTCQB: OPLI), jointly announced today that the U.S. Patent and Trademark Office granted a U.S. patent which bears the Patent No. 8,557,790 and is titled "A3 Adenosine receptor agonists for the reduction of intraocular pressure". Increased intraocular pressure ("IOP") is the most important and only modifiable risk factor for glaucoma. This patent was granted to Can-Fite and relates to the use of the drug candidate CF101. Pursuant to a license agreement between Can-Fite and OphthaliX's wholly owned subsidiary, EyeFite Ltd., OphthaliX has the exclusive rights for the use and development of CF101 for the reduction of IOP in the United States until 2030.
Can-Fite BioPharma to Conduct European Road Show
PR Newswire - Tue Nov 05, 6:00AM CST
Can-Fite BioPharma (TASE: CFBI), (OTCQB: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Company's CEO Dr. Pnina Fishman will conduct a non-deal European road show on November 11th through 13th, 2013. A series of one-on-one meetings and group presentations are scheduled in Zurich on November 11th, Geneva on November 12th, and Paris on November 13th.